Is Egrifta (Tesamorelin) Legal in Alabama?

Federal Legal Framework: Why FDA Approval Matters First

Alabama cannot grant or deny federal drug approval. The starting point for any legality question about tesamorelin is therefore federal law, specifically the Food, Drug, and Cosmetic Act and FDA's approval record.

Tesamorelin was approved by the FDA in November 2010 under the brand name Egrifta for the reduction of excess abdominal fat (lipodystrophy) in HIV-infected adults [1]. A second approval followed in May 2019, expanding the label to HIV-infected adults 40 years of age and older with a confirmed diagnosis of HIV-associated lipodystrophy [2]. Because tesamorelin holds these approvals, it travels through the normal prescription drug supply chain and is not subject to the legal uncertainty that surrounds unapproved research peptides.

Tesamorelin Is Not a Controlled Substance

The Drug Enforcement Administration classifies controlled substances under Schedules I through V [3]. Tesamorelin appears on none of these schedules. It is a synthetic analogue of endogenous growth hormone-releasing hormone (GHRH), not an anabolic steroid, opioid, or stimulant. Alabama mirrors federal scheduling through the Alabama Uniform Controlled Substances Act (Code of Alabama § 20-2-1 et seq.), and tesamorelin is absent from both lists [4].

This distinction is clinically meaningful. A Schedule III anabolic steroid like testosterone requires a DEA-number-linked triplicate process; tesamorelin requires only a standard written or electronic prescription.

How FDA Approval Defines the Legal Supply Chain

FDA approval means Egrifta SV (the current formulation, 2 mg/vial) may be manufactured, distributed, and dispensed only through licensed channels: FDA-registered manufacturers, state-licensed wholesalers, and state-licensed pharmacies [5]. Purchasing tesamorelin from an overseas website, a gym contact, or any non-licensed vendor violates federal law regardless of the buyer's state of residence.

Alabama State Law: What Governs Prescribing and Dispensing

Alabama Board of Medical Examiners and the Medical Practice Act

In Alabama, the prescribing of any legend drug (a drug requiring a prescription) is governed by the Alabama Medical Practice Act (Code of Alabama § 34-24-50 et seq.) and the Alabama Board of Medical Examiners (BME). Physicians, nurse practitioners, and physician assistants who hold a current Alabama license and DEA registration may prescribe tesamorelin for any indication supported by their clinical judgment, including FDA-approved indications [6].

The BME's standard of care language requires that a prescription be issued only within a legitimate patient-physician relationship, supported by an adequate history, physical examination or equivalent telehealth evaluation, and documented medical necessity. Prescribing tesamorelin solely for cosmetic body composition changes without the underlying HIV-associated lipodystrophy diagnosis would fall outside the approved labeling and could expose the prescriber to BME disciplinary action.

Alabama State Board of Pharmacy and Dispensing Rules

The Alabama State Board of Pharmacy (ALBOP) licenses all retail, specialty, and compounding pharmacies operating in the state [7]. Any licensed Alabama pharmacy can order and dispense Egrifta SV once a valid prescription is presented. ALBOP rules align with federal USP standards for storage and handling of biologics and peptide drugs, including cold-chain requirements for tesamorelin (refrigerated at 2°C to 8°C prior to reconstitution) [8].

Telehealth Prescribing in Alabama

Alabama law permits telehealth prescribing under the Alabama Telehealth Act (Act 2015-387, later amended) and BME Rule 540-X-9. A prescriber may evaluate a patient via synchronous audio-visual telehealth and issue a prescription for tesamorelin if the standard of care obligations (history, documented diagnosis, informed consent) are met [9]. This pathway is relevant for patients in rural Alabama counties who lack local access to infectious disease or endocrinology specialists.

Compounded Tesamorelin in Alabama: A Legally Complex Path

The FDA 503B Bulks List

Compounded versions of tesamorelin occupy a narrower legal space than the branded product. The FDA Center for Drug Evaluation and Research (CDER) maintains a list of bulk drug substances that may be used by outsourcing facilities (503B facilities) registered under Section 503B of the FD&C Act [10]. Tesamorelin was evaluated for inclusion on this list, and FDA's assessment raised concerns about clinical necessity given the availability of the approved product. Providers and patients should verify the current status of tesamorelin on the 503B bulks list directly with FDA before pursuing this route, as the list is updated periodically [11].

503A Traditional Compounding Pharmacies

A 503A pharmacy (a traditional state-licensed compounding pharmacy) may compound a drug that is essentially a copy of a commercially available product only under specific circumstances: a prescriber documents a medical necessity for a different route, strength, or formulation that the commercial product cannot provide [12]. Given that Egrifta SV is available in a single 2 mg/vial subcutaneous injection format, documenting a compelling 503A rationale for tesamorelin is difficult. Alabama compounding pharmacies operating under ALBOP licensure must comply with both state rules and federal USP 797 standards [13].

The practical takeaway: for the vast majority of Alabama patients with a documented HIV-associated lipodystrophy diagnosis, the FDA-approved Egrifta SV is the legally cleanest and clinically validated path. Compounded tesamorelin carries regulatory and quality-control risks that the branded product does not.

Clinical Evidence Supporting the Approved Indication

Key Phase 3 Trial Data

The FDA approval rests primarily on two randomized controlled trials (LIPO-010 and a confirmatory study), each demonstrating that tesamorelin 2 mg subcutaneously once daily significantly reduced visceral adipose tissue (VAT) in HIV-infected adults compared with placebo [14]. In the pooled analysis published in the New England Journal of Medicine, tesamorelin reduced VAT by approximately 15% from baseline at 26 weeks (P<0.001 versus placebo), with IGF-1 levels rising but remaining within the normal range in most participants [15].

Metabolic and Lipid Effects

Tesamorelin's mechanism is indirect: it binds to GHRH receptors on pituitary somatotrophs, stimulating pulsatile growth hormone (GH) secretion, which in turn elevates insulin-like growth factor 1 (IGF-1) and promotes lipolysis in visceral adipose tissue [16]. A 2014 study in the Journal of Clinical Endocrinology and Metabolism (N=273) found that triglyceride levels fell by a mean of 50.5 mg/dL in tesamorelin-treated patients versus a 3.1 mg/dL change in the placebo group at 52 weeks [17]. Glucose and insulin resistance markers showed modest but not clinically alarming changes at the 2 mg approved dose.

Quality-of-Life Data

Beyond metabolic metrics, a validated body image instrument (ABIS) showed statistically significant improvements in body image distress scores at 26 weeks in patients receiving tesamorelin versus placebo [18]. This patient-reported outcome was part of the FDA's basis for approval and is directly relevant to clinicians documenting medical necessity for Alabama patients.

Off-Label Use: What Alabama Prescribers Need to Know

Off-label prescribing is legal under both federal and Alabama law. The FDA explicitly does not restrict physicians from prescribing approved drugs for unapproved uses when supported by clinical evidence [19]. Small studies have examined tesamorelin in non-HIV populations, including older adults with age-related visceral adiposity. A 2012 study in the Journal of Clinical Endocrinology and Metabolism (N=89, mean age 64) found tesamorelin 2 mg/day reduced VAT by 9.6 cm² after 6 months in non-HIV participants, though this population is not included in the labeling [20].

Alabama prescribers who write tesamorelin for off-label indications should document: the specific clinical rationale, the supporting evidence reviewed, the absence of contraindications (active malignancy, pregnancy, hypopituitarism not on stable replacement, or acute critical illness), and informed consent confirming the patient understands the use is not FDA-approved for their condition [21].

How to Get an Egrifta Prescription in Alabama: Step-by-Step

Step 1. Confirm the Indication

The FDA-approved indication is HIV-associated lipodystrophy confirmed by imaging or clinical assessment. Before scheduling any appointment, obtain records documenting HIV status, current antiretroviral therapy, and (ideally) prior VAT imaging such as a CT scan or DEXA-based visceral fat estimate.

Step 2. Find a Qualified Prescriber

Infectious disease physicians and endocrinologists are the specialists most familiar with tesamorelin prescribing. In Alabama, the University of Alabama at Birmingham (UAB) Division of Infectious Diseases and the UAB Comprehensive HIV Program are primary referral centers. Telehealth platforms licensed in Alabama can also connect patients with endocrinology or HIV medicine specialists who can evaluate the indication remotely.

Step 3. Obtain the Prescription and Fill It

Egrifta SV requires specialty pharmacy distribution in most cases due to cold-chain logistics and prior authorization requirements from major insurers. Specialty pharmacies such as those accredited by URAC or ACHC and licensed in Alabama can dispense the product. The manufacturer (Theratechnologies) maintains a patient support program that includes prior authorization assistance and co-pay support for eligible patients [22].

Step 4. Ongoing Monitoring

After starting tesamorelin, prescribers should monitor IGF-1 levels at 6 to 8 weeks to confirm the level stays within the age-normalized reference range [14]. Fasting glucose and HbA1c checks at baseline and every 6 months are prudent given the drug's GH-mediated effect on insulin sensitivity [15]. Dose titration is not standard; the approved dose is 2 mg once daily with no published efficacy data at higher doses for the labeled indication.

Insurance Coverage and Cost Considerations in Alabama

Medicaid Alabama (provided through Alabama Medicaid Agency) covers Egrifta SV for eligible HIV-positive beneficiaries when medical necessity criteria are met, including a documented lipodystrophy diagnosis and prior authorization [23]. Medicare Part D coverage varies by plan formulary; most Part D plans place Egrifta SV in a specialty tier requiring step therapy or prior authorization.

Without insurance, Egrifta SV carries a list price exceeding $5,000 per month. The Theratechnologies patient assistance program (EGRIFTAssist) provides free drug to uninsured patients who meet income criteria, and this program is available to Alabama residents [22].

Summary Table: Legal Pathways for Tesamorelin in Alabama

| Pathway | Legal Status | Key Requirement | |---|---|---| | Branded Egrifta SV via specialty pharmacy | Fully legal | Valid prescription, licensed Alabama pharmacy | | 503B compounded tesamorelin | Restricted, verify current FDA bulks list status | Must not be essentially a copy of approved product | | 503A compounded tesamorelin | Narrow exceptions only | Documented medical necessity for alternate formulation | | Overseas/unlicensed internet purchase | Illegal under federal law | No legal pathway exists | | Telehealth prescription in Alabama | Legal under Alabama Telehealth Act | Synchronous AV evaluation, documented diagnosis |